Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide.Methods: Lira-1 was a randomized, d...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-04-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2019.00242/full |
| _version_ | 1819102256492969984 |
|---|---|
| author | Christian Stevns Hansen Christian Seerup Frandsen Jesper Fleischer Dorte Vistisen Jens Juul Holst Jens Juul Holst Lise Tarnow Filip Krag Knop Filip Krag Knop Filip Krag Knop Sten Madsbad Sten Madsbad Henrik Ullits Andersen Thomas Fremming Dejgaard Thomas Fremming Dejgaard |
| author_facet | Christian Stevns Hansen Christian Seerup Frandsen Jesper Fleischer Dorte Vistisen Jens Juul Holst Jens Juul Holst Lise Tarnow Filip Krag Knop Filip Krag Knop Filip Krag Knop Sten Madsbad Sten Madsbad Henrik Ullits Andersen Thomas Fremming Dejgaard Thomas Fremming Dejgaard |
| author_sort | Christian Stevns Hansen |
| collection | DOAJ |
| description | The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide.Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models.Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA1c 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m2 were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of −2.65 kg during the trial (95% CI: −4.60; −0.69; P = 0.009). Similar significant associations were found for several HRV indices.Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist. |
| first_indexed | 2024-12-22T01:31:40Z |
| format | Article |
| id | doaj.art-9de8070814644870b0a0939aab535341 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-22T01:31:40Z |
| publishDate | 2019-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-9de8070814644870b0a0939aab5353412022-12-21T18:43:28ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922019-04-011010.3389/fendo.2019.00242452702Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 DiabetesChristian Stevns Hansen0Christian Seerup Frandsen1Jesper Fleischer2Dorte Vistisen3Jens Juul Holst4Jens Juul Holst5Lise Tarnow6Filip Krag Knop7Filip Krag Knop8Filip Krag Knop9Sten Madsbad10Sten Madsbad11Henrik Ullits Andersen12Thomas Fremming Dejgaard13Thomas Fremming Dejgaard14Steno Diabetes Center Copenhagen, Gentofte, DenmarkDepartment of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, DenmarkClinical Institute of Medicine, Aarhus University, Århus, DenmarkSteno Diabetes Center Copenhagen, Gentofte, DenmarkDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkFaculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, DenmarkNordsjællands Hospital Hillerød, University of Copenhagen, Hillerød, DenmarkFaculty of Health and Medical Sciences, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, DenmarkClinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, DenmarkDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkDepartment of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, DenmarkDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSteno Diabetes Center Copenhagen, Gentofte, DenmarkSteno Diabetes Center Copenhagen, Gentofte, DenmarkDepartment of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, DenmarkThe role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide.Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models.Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA1c 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m2 were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of −2.65 kg during the trial (95% CI: −4.60; −0.69; P = 0.009). Similar significant associations were found for several HRV indices.Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.https://www.frontiersin.org/article/10.3389/fendo.2019.00242/fullliraglutideautonomic neuropathyweight lossinsulin requirementstype 1 diabetes |
| spellingShingle | Christian Stevns Hansen Christian Seerup Frandsen Jesper Fleischer Dorte Vistisen Jens Juul Holst Jens Juul Holst Lise Tarnow Filip Krag Knop Filip Krag Knop Filip Krag Knop Sten Madsbad Sten Madsbad Henrik Ullits Andersen Thomas Fremming Dejgaard Thomas Fremming Dejgaard Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes Frontiers in Endocrinology liraglutide autonomic neuropathy weight loss insulin requirements type 1 diabetes |
| title | Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes |
| title_full | Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes |
| title_fullStr | Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes |
| title_full_unstemmed | Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes |
| title_short | Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes |
| title_sort | liraglutide induced weight loss may be affected by autonomic regulation in type 1 diabetes |
| topic | liraglutide autonomic neuropathy weight loss insulin requirements type 1 diabetes |
| url | https://www.frontiersin.org/article/10.3389/fendo.2019.00242/full |
| work_keys_str_mv | AT christianstevnshansen liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT christianseerupfrandsen liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT jesperfleischer liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT dortevistisen liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT jensjuulholst liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT jensjuulholst liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT lisetarnow liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT filipkragknop liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT filipkragknop liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT filipkragknop liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT stenmadsbad liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT stenmadsbad liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT henrikullitsandersen liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT thomasfremmingdejgaard liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes AT thomasfremmingdejgaard liraglutideinducedweightlossmaybeaffectedbyautonomicregulationintype1diabetes |